MapLight Therapeutics lost value after disclosing mid-stage results for its schizophrenia drug that were described as positive overall but raised concerns for investors about differentiation. The phase 2 study found twice-daily dosing improved symptoms compared with placebo on the primary schizophrenia scoring measure, while the once-daily regimen missed the primary endpoint. The company said the twice-daily schedule showed stronger effects in secondary testing and that it is evaluating whether the once-daily approach can still find a path forward. MapLight’s muscarinic receptor mechanism is positioned against Bristol Myers Squibb’s approved therapy, Cobenfy, which has already set a high bar for efficacy and patient adherence. The stock reaction reflects a core commercialization risk for CNS companies: whether dosing convenience can be matched without sacrificing signal strength or tolerability.